Fulgent Therapeutics, LLC.
Fulgent Therapeutics, LLC. was paid $84.90M by Medicaid between Oct 2018 and Jul 2024, across 33 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 78% of everything it billed.
EL MONTE, CA 91731
Next to other Clinical Medical Laboratory providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12 | $16K | |
| 2019 | 47 | $45K | |
| 2020 | 236,650 | $15.51M | |
| 2021 | 1,230,348 | $40.44M | |
| 2022 | 865,367 | $28.33M | |
| 2023 | 12,180 | $492K | |
| 2024incomplete | 1,398 | $73K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 78% | 1,237,212 | 888,342 | $66.13M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 8.9% | 704,253 | 501,282 | $7.52M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 6.5% | 330,778 | 224,376 | $5.53M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 6.2% | 58,236 | 45,229 | $5.23M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 9,573 | 7,647 | $249K |
| 81479 | Unlisted molecular pathology procedure | <1% | 706 | 659 | $91K |
| 81406 | <1% | 556 | 540 | $61K | |
| 81329 | <1% | 614 | 601 | $22K | |
| 81222 | <1% | 532 | 518 | $19K | |
| 0003A | <1% | 608 | 607 | $13K | |
| 0001A | <1% | 852 | 851 | $12K | |
| 0002A | <1% | 699 | 699 | $10K |
21 more codes
| 0013A | <1% | 394 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 130 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 30 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 26 | $1K |
| 0012A | <1% | 153 | $853.63 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 48 | $467.55 |
| 0011A | <1% | 138 | $177.58 | |
| 81361 | <1% | 39 | $97.90 | |
| 81257 | <1% | 38 | $57.26 | |
| 0031A | <1% | 29 | $40.59 | |
| 81243 | <1% | 39 | $31.94 | |
| 81255 | <1% | 39 | $28.82 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 14 | $27.50 |
| 81200 | <1% | 39 | $26.46 | |
| 81251 | <1% | 39 | $26.46 | |
| 81330 | <1% | 17 | $26.32 | |
| 81209 | <1% | 39 | $22.02 | |
| 81260 | <1% | 39 | $22.02 | |
| 81290 | <1% | 39 | $22.02 | |
| 81242 | <1% | 39 | $20.50 | |
| 81443 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Fulgent Therapeutics, LLC. | El Monte, CA | $1.56M |
| Paul H. Kim M.D., INC., a Professional Corporation | Torrance, CA | $339K |
| Cal City Urgent Care | California City, CA | $227K |
| Bradshaw Optometry Corp | Sacramento, CA | $176K |
| Paul J Kim MD INC | Tustin, CA | $157K |
| DR. P.Kim Podiatry, P.C. | Brooklyn, NY | $104K |
| Bradshaw Optometry | Elk Grove, CA | $80K |
| Grace Hematology and Oncology | Fletcher, NC | $36K |
| Thinknetic Medical Corporation | San Bernardino, CA | $33K |
| Paul E Kim MD INC | San Diego, CA | $11K |
| Sun City Optometry a Professional Corporation | Menifee, CA | $685.24 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.